A5063856692- BRCA gene mutations in cancer
- Breast Cancer Treatment Studies
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- Ovarian cancer diagnosis and treatment
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Colorectal Cancer Screening and Detection
- Genetic factors in colorectal cancer
- Genomic variations and chromosomal abnormalities
- PARP inhibition in cancer therapy
- Cancer-related molecular mechanisms research
- Estrogen and related hormone effects
- Endometrial and Cervical Cancer Treatments
- DNA Repair Mechanisms
- Reproductive Biology and Fertility
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- AI in cancer detection
- Cancer Cells and Metastasis
- Nutrition, Genetics, and Disease
- Genetic Associations and Epidemiology
- Colorectal and Anal Carcinomas
- Diversity and Career in Medicine
- Gastric Cancer Management and Outcomes
Women's College Hospital
2014-2023
University of Toronto
2014-2022
Public Health Ontario
2019-2020
International Hereditary Cancer Center
2017
Pomeranian Medical University
2017
Women with ductal carcinoma in situ (DCIS), or stage 0 breast cancer, often experience a second primary cancer (DCIS invasive), and some ultimately die of cancer.To estimate the 10- 20-year mortality from following diagnosis DCIS to establish whether rate is influenced by age at diagnosis, ethnicity, initial treatment received.Observational study women who received 1988 2011 Surveillance, Epidemiology, End Results (SEER) 18 registries database. Age race/ethnicity, pathologic features, date...
In patients with breast cancer, increasing tumour size at diagnosis is associated an increased likelihood of axillary lymph node involvement and cancer-specific mortality. However, this relation based on studies which combine all tumours smaller than 1.0 cm in a single category larger 5.0 another category. This coarse classification may obscure nuanced description the effects across full range possible sizes. We examined relationship between primary size, status distant metastases cohort...
<h3>Importance</h3> It is not clear to what extent a diagnosis of ductal carcinoma in situ (DCIS) impacts woman's lifetime risk dying breast cancer. Under ideal circumstances, treatment will eliminate the invasive ipsilateral recurrence and prevent subsequent mortality from The cancer after DCIS had been compared with that women without general population. <h3>Objective</h3> To determine death large cohort patients treated for compare <h3>Design, Setting, Participants</h3> This study...
A number of genes other than BRCA1 and BRCA2 have been associated with breast cancer predisposition, extended genetic testing panels proposed. It is interest to establish the full spectrum deleterious mutations in women familial cancer.We performed whole‐exome sequencing 144 negative for 11 Polish founder , CHEK2 NBS1 we evaluated sequences 12 known susceptibility genes. truncating mutation a gene was detected 24 (17%) cancer. cases, (non‐founder) 5 PALB2 4 cases an ATM 2 cases. who are...
Mutations in the BRCA1, BRCA2 and PALB2 genes are well-established risk factors for development of breast and/or ovarian cancer. The frequency spectrum mutations these has not yet been examined population Southern Poland.We entire coding sequences BRCA1 genotyped a recurrent mutation gene (c.509_510delGA) 121 women with familial early-onset or cancer from Poland.A was identified 11 patients (9.1 %) 10 (8.3 %). Two founder accounted 91 % all carriers (c.5266dupC six c.181 T > G four...
<h3>Importance</h3> Patients with ductal carcinoma in situ (DCIS) are treated radiotherapy to reduce their risk of local invasive recurrence after breast-conserving surgery. However, the association breast cancer survival patients DCIS has not yet been clearly established. <h3>Objective</h3> To determine extent which is associated reduced mortality a large cohort for DCIS, using propensity score–based matching approach. <h3>Design, Setting, and Participants</h3> This study women who had...
To describe the mortality experience of women who die breast cancer in 20-year period post-diagnosis using various metrics, including annual rates, Kaplan-Meier survival curves and time-to-death histograms.We generated three visual representations SEER-based hospital-based patient cohorts different metrics mortality.The greatest impact most prognostic factors was on probability latent metastases present after treatment, but for some primary time to death those with metastases.The use...
Background: Many women with early-stage breast cancer are predicted to be at sufficiently low risk for recurrence that they may forego chemotherapy. Nevertheless, some low-risk will experience a local recurrence, and them the of death increases significantly thereafter. The utility initiating chemotherapy time has not been adequately addressed. purpose this study is identify, in hospital-based series patients who were treated chemotherapy, those factors which predict post recurrence....